Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

BRANDON LENOX

Allopathic & Osteopathic Physicians Anesthesiology

NPI
1710023098
CMS profile
469116
Location
MAITLAND, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$11.87

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $11.87 1

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
3M Company $11.87 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

BRANDON LENOX

NPI 1710023098 · CMS profile ID 469116

Allopathic & Osteopathic Physicians / Anesthesiology

MAITLAND, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1710023098?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
BRANDON LENOX, NPI 1710023098, CMS profile ID 469116. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1710023098?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). BRANDON LENOX, NPI 1710023098, CMS profile ID 469116. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1710023098?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
BRANDON LENOX, NPI 1710023098, CMS profile ID 469116, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1710023098?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $11.87 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
3M Company $11.8710/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 619315855 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $11.87 1
PY2021 $14.90 1
PY2022 $289.02 3
PY2023 $141.36 2
PY2024 $2,161.67 16
PY2025 $3,301.84 7

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $13,276,611.80 216
PY2024 Principal investigator $6,638,229.38 94
PY2023 Recipient $18,535.52 1
PY2023 Principal investigator $6,796,584.13 63
PY2022 Recipient $75,198.00 3
PY2022 Principal investigator $5,184,921.00 42
PY2021 Recipient $4,330.51 1
PY2021 Principal investigator $6,000.00 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

94 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $927.00 12/31/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH MAITLAND LLC
M23-515 Ph2 AD Global Study No dispute reported 06/30/2026 1100764609
Principal investigator 1 Janssen Research & Development, LLC $540.00 12/20/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1079018364
Principal investigator 1 Janssen Research & Development, LLC $540.00 12/20/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1079018382
Principal investigator 1 Janssen Research & Development, LLC $2,639.00 12/16/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1079018342
Principal investigator 1 Janssen Research & Development, LLC $89,145.00 12/13/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1079018360
Principal investigator 1 Janssen Research & Development, LLC $75,113.00 12/13/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1079018390
Principal investigator 1 ABBVIE INC. $300.00 12/09/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH MAITLAND LLC
Study to Assess Adverse Events Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer s Disease No dispute reported 06/30/2026 1100760537
Principal investigator 1 Eli Lilly and Company $213,732.00 12/09/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE No dispute reported 06/30/2026 1137360645
Principal investigator 1 Janssen Research & Development, LLC $25,300.00 12/06/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1079018330
Principal investigator 1 Janssen Research & Development, LLC $80,920.00 12/06/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1079018338
Principal investigator 1 Janssen Research & Development, LLC $75,140.00 12/06/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1079018346
Principal investigator 1 Janssen Research & Development, LLC $8,102.00 12/06/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1079018352
Principal investigator 1 Janssen Research & Development, LLC $12,650.00 12/06/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1079018358
Principal investigator 1 Janssen Research & Development, LLC $32,408.00 12/06/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1079018366
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $78,180.95 12/02/2024 Non-covered Recipient Entity
K2 Medical Research - Maitland
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects with Psychosis Associated with Alzheimers Disease Dementia No dispute reported 06/30/2026 1123477961
Principal investigator 1 ModernaTX, Inc. $132,871.07 11/27/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age No dispute reported 06/30/2026 1147181221
Principal investigator 1 Janssen Research & Development, LLC $2,681.00 11/08/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1079018362
Principal investigator 1 Janssen Research & Development, LLC $760,822.00 11/06/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1079018354
Principal investigator 1 Janssen Research & Development, LLC $101,766.00 11/04/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1079018340
Principal investigator 1 Janssen Research & Development, LLC $436,140.00 11/04/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1079018388
Principal investigator 1 Eli Lilly and Company $390.00 10/31/2024 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A SINGLE- AND MULTIPLE-ASCENDING DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF LY3954068 IN PATIENTS WITH EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1137353334
Principal investigator 1 Eli Lilly and Company $28,760.33 10/28/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE No dispute reported 06/30/2026 1137360725
Principal investigator 1 ModernaTX, Inc. $1,050.00 10/21/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age No dispute reported 06/30/2026 1147181217
Principal investigator 1 ModernaTX, Inc. $8,975.00 10/21/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age No dispute reported 06/30/2026 1147181219
Principal investigator 1 Janssen Research & Development, LLC $109,035.00 10/14/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1079018348
Principal investigator 1 Janssen Research & Development, LLC $329,528.00 10/14/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1079018380
Principal investigator 1 Janssen Research & Development, LLC $2,681.00 10/04/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1079018372
Principal investigator 1 ABBVIE INC. $2,174.00 10/03/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH MAITLAND LLC
Study to Assess Adverse Events Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer s Disease No dispute reported 06/30/2026 1100746704
Principal investigator 1 ABBVIE INC. $28,941.00 09/03/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH MAITLAND LLC
Study to Assess Adverse Events Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer s Disease No dispute reported 06/30/2026 1100739388
Principal investigator 1 Janssen Research & Development, LLC $17,643.00 08/29/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1079018336
Principal investigator 1 ModernaTX, Inc. $598.68 08/20/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age No dispute reported 06/30/2026 1147181215
Principal investigator 1 Janssen Research & Development, LLC $540.00 08/19/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1079018332
Principal investigator 1 ABBVIE INC. $559.00 08/02/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH MAITLAND LLC
Study to Assess Adverse Events Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer s Disease No dispute reported 06/30/2026 1100734076
Principal investigator 1 Janssen Research & Development, LLC $15,027.00 08/01/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1079018370
Principal investigator 1 BioXcel Therapeutics, Inc. $89,932.03 07/24/2024 Non-covered Recipient Entity
K-2 RESEARCH
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EFFICACY AND SAFETY STUDY OF PRN DOSING OF BXCL501 OVER A 12 WEEK TREATMENT PERIOD IN SUBJECTS WITH AGITATION ASSOCIATED WITH DEMENTIA WHO REQUIRE AT LEAST MODERATE TO FULL ASSISTANCE WITH ACTIVITIES OF DAILY LIVING No dispute reported 06/30/2026 1150029789
Principal investigator 1 BioXcel Therapeutics, Inc. $32,487.68 07/24/2024 Non-covered Recipient Entity
K-2 RESEARCH
EVALUATION OF BXCL501 PLACEBO INSTRUCTIONS FOR USE AND COMPREHENSION OF TRAINING FOR CAREGIVERS AND PARTICIPANTS WITH AGITATION ASSOCIATED WITH ALZHEIMERS DEMENTIA PARTICIPATING IN STUDIES INVESTIGATING AT-HOME ADMINISTRATION No dispute reported 06/30/2026 1150029791
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $133,075.00 07/19/2024 Non-covered Recipient Entity
K2 Medical Research
A Phase 3, Randomized, Double-blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated with Alzheimers Disease Dementia No dispute reported 06/30/2026 1123477953
Principal investigator 1 ABBVIE INC. $3,234.00 07/05/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH MAITLAND LLC
Study to Assess Adverse Events Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer s Disease No dispute reported 06/30/2026 1100727232
Principal investigator 1 Janssen Research & Development, LLC $2,616.00 07/04/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1079018368
Principal investigator 1 Eli Lilly and Company $5,186.95 07/01/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A SINGLE- AND MULTIPLE-ASCENDING DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF LY3954068 IN PATIENTS WITH EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1137360657
Principal investigator 1 Janssen Research & Development, LLC $368.00 06/17/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1079018384
Principal investigator 1 Janssen Research & Development, LLC $14,739.00 06/07/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1079018356
Principal investigator 1 ABBVIE INC. $55,657.00 06/05/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH MAITLAND LLC
Study to Assess Adverse Events Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimers Disease No dispute reported 06/30/2026 1100721094
Principal investigator 1 Janssen Research & Development, LLC $22,310.00 05/31/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1079018334
Principal investigator 1 ABBVIE INC. $1,575.00 05/30/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH MAITLAND LLC
Study to Assess Adverse Events Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimers Disease No dispute reported 06/30/2026 1100720114
Principal investigator 1 ABBVIE INC. $7,500.00 05/23/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH MAITLAND LLC
Study to Assess Adverse Events Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimers Disease No dispute reported 06/30/2026 1100719556
Principal investigator 1 ABBVIE INC. $17,536.00 05/08/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH MAITLAND LLC
Study to Assess Adverse Events Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimers Disease No dispute reported 06/30/2026 1100716538
Principal investigator 1 Janssen Research & Development, LLC $5,400.00 05/03/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1079018344
Principal investigator 1 Janssen Research & Development, LLC $7,234.00 04/29/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1079018350
Principal investigator 1 Eli Lilly and Company $21,200.00 04/15/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
ASSESSMENT OF SAFETY AND EFFICACY OF INTRAVENOUS REMTERNETUG IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 1137360651
Principal investigator 1 Janssen Research & Development, LLC $800.00 04/15/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1079018386
Principal investigator 1 Bavarian Nordic A/S $2,439.00 04/12/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 1119662712
Principal investigator 1 ABBVIE INC. $10,560.00 04/04/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH MAITLAND LLC
Study to Assess Adverse Events Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimers Disease No dispute reported 06/30/2026 1100712132
Principal investigator 1 Bavarian Nordic A/S $1,800.00 04/04/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 1119662680
Principal investigator 1 Bavarian Nordic A/S $3,600.00 04/04/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 1119662690
Principal investigator 1 Bavarian Nordic A/S $3,336.00 04/04/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 1119662694
Principal investigator 1 Bavarian Nordic A/S $3,360.00 04/04/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 1119662702
Principal investigator 1 Bavarian Nordic A/S $4,200.00 04/04/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 1119662706
Principal investigator 1 Bavarian Nordic A/S $3,000.00 04/04/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 1119662710
Principal investigator 1 Bavarian Nordic A/S $2,000.00 04/04/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 1119662904
Principal investigator 1 Janssen Research & Development, LLC $1,216.00 04/01/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1079018374
Principal investigator 1 ABBVIE INC. $2,250.00 03/28/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH MAITLAND LLC
Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimers Disease No dispute reported 06/30/2026 1100710132
Principal investigator 1 Bavarian Nordic A/S $47,537.00 03/26/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 1119662700
Principal investigator 1 Bavarian Nordic A/S $13,406.48 03/26/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 1119662718
Principal investigator 1 Bavarian Nordic A/S $1,650.00 03/21/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 1119662682
Principal investigator 1 Bavarian Nordic A/S $3,300.00 03/21/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 1119662692
Principal investigator 1 Bavarian Nordic A/S $3,058.00 03/21/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 1119662698
Principal investigator 1 Bavarian Nordic A/S $3,080.00 03/21/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 1119662704
Principal investigator 1 Bavarian Nordic A/S $3,850.00 03/21/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 1119662708
Principal investigator 1 Bavarian Nordic A/S $2,750.00 03/21/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 1119662714
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $451,855.06 03/20/2024 Non-covered Recipient Entity
K2 Medical Research - Maitland
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Relapse Prevention Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated with Alzheimers Disease No dispute reported 06/30/2026 1123477959
Principal investigator 1 ABBVIE INC. $8,868.00 03/07/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH MAITLAND LLC
Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimers Disease No dispute reported 06/30/2026 1100706090
Principal investigator 1 Janssen Research & Development, LLC $2,729.00 03/04/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1079018378
Principal investigator 1 Bavarian Nordic A/S $6,500.00 02/29/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 1119662676
Principal investigator 1 Bavarian Nordic A/S $1,755.00 02/29/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 1119662678
Principal investigator 1 Bavarian Nordic A/S $3,600.00 02/29/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 1119662684
Principal investigator 1 Bavarian Nordic A/S $1,000.00 02/29/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 1119662686
Principal investigator 1 Bavarian Nordic A/S $1,060.00 02/29/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 1119662688
Principal investigator 1 Bavarian Nordic A/S $1,200.00 02/29/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 1119662716
Principal investigator 1 Bavarian Nordic A/S $7,020.00 02/29/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 1119662720
Principal investigator 1 Bavarian Nordic A/S $970.00 02/29/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 1119662906
Principal investigator 1 ABBVIE INC. $7,500.00 02/27/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH MAITLAND LLC
Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimers Disease No dispute reported 06/30/2026 1100705056
Principal investigator 1 ABBVIE INC. $1,500.00 02/20/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH MAITLAND LLC
Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimers Disease No dispute reported 06/30/2026 1100704192
Principal investigator 1 Janssen Research & Development, LLC $24,812.00 02/08/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1079018376
Principal investigator 1 ABBVIE INC. $100.00 02/01/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH MAITLAND LLC
Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimers Disease No dispute reported 06/30/2026 1100701636
Principal investigator 1 Eli Lilly and Company $3,910.20 01/31/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3372689 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1137360653
Principal investigator 1 Eli Lilly and Company $50.40 01/29/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A STUDY OF DIFFERENT DONANEMAB (LY3002813) DOSING REGIMENS IN ADULTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 6) No dispute reported 06/30/2026 1137361529
Principal investigator 1 Eli Lilly and Company $12,408.24 01/17/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1137361329
Principal investigator 1 Eli Lilly and Company $931,930.58 01/16/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1137361527
Principal investigator 1 Eli Lilly and Company $328,074.00 01/09/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1137361327
Principal investigator 1 Eli Lilly and Company $243,806.00 01/09/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3372689 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1137361525
Principal investigator 1 Eli Lilly and Company $15,568.73 01/09/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1137361531
Principal investigator 1 Bavarian Nordic A/S $215.00 01/05/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 1119662696
Principal investigator 1 Eli Lilly and Company $1,368,735.00 01/02/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A STUDY OF DIFFERENT DONANEMAB (LY3002813) DOSING REGIMENS IN ADULTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 6) No dispute reported 06/30/2026 1137361323